Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Enhertu Filed for HER2 Mutant Metastatic NSCLC: Daiichi Sankyo
December 14, 2022
- Daiichi Sankyo’s TROP2-Directed ADC Shows Promising Data for Triple Negative Breast Cancer
December 13, 2022
- Estimated 1,024 Patients Took Xocova in First 11 Days: Shionogi
December 13, 2022
- RaQualia, DWTI Tie Up on Eye Disease Drug Research
December 13, 2022
- Minimum Age for Moderna Boosters Lowered to 12 Years Old in Japan
December 13, 2022
- Astellas CEO Vows Bold Investment in Targeted Protein Degradation to Fuel Drug Discovery
December 12, 2022
- Chugai, Towa Release Edirol’s Tablet Form in Japan
December 12, 2022
- Berinert SC Injection Holds Promise as “First Choice” for HAE Attacks: CSL Japan Chief
December 9, 2022
- CSL to Bring 1st Hemophilia B Gene Therapy to Japan Too; Eyes Riveted on Price Tag
December 9, 2022
- Merck CEO Wants to See Japan’s Shift to Pro-Innovation Structure in 2024 Reform
December 9, 2022
- Gilead to Take Over Yescarta Marketing Authorization in Japan
December 9, 2022
- UCB Files C5 Inhibitor Zilucoplan for Japan Approval
December 9, 2022
- Moderna CMO Hints at Filing Cancer Vaccine with PII Data, Topline Readout Soon
December 8, 2022
- Japan Ethical Drug Sales Up 1.8% in October: Crecon
December 8, 2022
- Kyowa Kirin, MEI Drop PI3Kδ Inhibitor Outside Japan after US FDA Guidance
December 7, 2022
- Francis Vaillant to Succeed Shingo Iwamoto as Sandoz Japan President
December 7, 2022
- Kyowa Kirin Rolls Out Automated Injection Device of G-Lasta in Japan
December 7, 2022
- Ono Gets Its Hands on Equillium’s Rights to 1st-in-Class CD6 Drug
December 7, 2022
- Opdivo Tops Japan Drug Sales Ranking for 11 Months on End: Encise
December 7, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…